Radlicka Anna, Kamińska Kinga, Borczyk Malgorzata, Piechota Marcin, Korostyński Michał, Pera Joanna, Lorenc-Koci Elżbieta, Rodriguez Parkitna Jan
Department of Molecular Neuropharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków 31-343, Poland.
Department of Neuro-Psychopharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków 31-343, Poland.
eNeuro. 2021 Jan 21;8(1). doi: 10.1523/ENEURO.0234-20.2020. Print 2021 Jan-Feb.
The development of Parkinson's disease (PD) causes dysfunction of the frontal cortex, which contributes to the hallmark motor symptoms and is regarded as one of the primary causes of the affective and cognitive impairments observed in PD. Treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) alleviates motor symptoms but has mixed efficacy in restoring normal cognitive functions, which is further complicated by the psychoactive effects of the drug. We investigated how L-DOPA affects gene expression in the frontal cortex in an animal model of unilateral PD. We performed RNA sequencing (RNA-Seq) analysis of gene expression in the frontal cortex of rats with 6-hydroxydopamine (6-OHDA)-induced unilateral dopaminergic lesions treated with L-DOPA, for two weeks. The analysis of variance identified 48 genes with a significantly altered transcript abundance after L-DOPA treatment. We also performed a weighted gene coexpression network analysis (WGCNA), which resulted in the detection of five modules consisting of genes with similar expression patterns. The analyses led to three primary observations. First, the changes in gene expression induced by L-DOPA were bilateral, although only one hemisphere was lesioned. Second, the changes were not restricted to neurons but also appeared to affect immune or endothelial cells. Finally, comparisons with databases of drug-induced gene expression signatures revealed multiple nonspecific effects, indicating that a part of the observed response is a common pattern activated by multiple types of drugs in different target tissues. Taken together, our results identify cellular mechanisms in the frontal cortex that are involved in the response to L-DOPA treatment.
帕金森病(PD)的发展会导致额叶皮质功能障碍,这会导致标志性的运动症状,并被认为是PD中观察到的情感和认知障碍的主要原因之一。用L-3,4-二羟基苯丙氨酸(L-DOPA)治疗可缓解运动症状,但在恢复正常认知功能方面疗效不一,而且该药物的精神活性作用使情况更加复杂。我们研究了在单侧PD动物模型中L-DOPA如何影响额叶皮质中的基因表达。我们对用L-DOPA治疗两周的、由6-羟基多巴胺(6-OHDA)诱导的单侧多巴胺能损伤大鼠的额叶皮质进行了基因表达的RNA测序(RNA-Seq)分析。方差分析确定了48个基因,其转录本丰度在L-DOPA治疗后有显著改变。我们还进行了加权基因共表达网络分析(WGCNA),结果检测到由具有相似表达模式的基因组成的五个模块。这些分析得出了三个主要观察结果。第一,尽管只有一个半球受损,但L-DOPA诱导的基因表达变化是双侧的。第二,这些变化不仅限于神经元,似乎还影响免疫细胞或内皮细胞。最后,与药物诱导的基因表达特征数据库进行比较,发现了多种非特异性效应,这表明观察到的部分反应是不同靶组织中多种类型药物激活的共同模式。综上所述,我们的结果确定了额叶皮质中参与对L-DOPA治疗反应的细胞机制。